1 / 17

Tecfidera ™ (dimethyl fumarate)

Tecfidera ™ (dimethyl fumarate). Manufacturer: Biogen/Idec FDA Approval Date: March 27, 2013. Tecfidera ™ (dimethyl fumarate) Clinical Application. Indications : First line therapy for relapsing-remitting forms of multiple sclerosis (RRMS) Place in therapy:

gale
Download Presentation

Tecfidera ™ (dimethyl fumarate)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Tecfidera™(dimethyl fumarate) Manufacturer: Biogen/Idec FDA Approval Date: March 27, 2013

  2. Tecfidera™ (dimethyl fumarate)Clinical Application • Indications: • First line therapy for relapsing-remitting forms of multiple sclerosis (RRMS) • Place in therapy: • Oral, possibly mildest ADE profile of all oral and non-oral alternatives; efficacy testing vs other agents is required

  3. Tecfidera™ (dimethyl fumarate)Clinical Application • Contraindications: • none • Warnings/Precautions • Lymphopenia – 30% reduction in lymphocyte count over 1st year, then stable • Flushing – similar to niacin; can be alleviated with food, Canadian labeling recommends premedication with aspirin for first week of therapy

  4. Tecfidera™ (dimethyl fumarate)Clinical Application • Pregnancy: • Category C – some evidence of harm in animals • Lactation: • Excretion in breast milk unknown; not recommended

  5. Tecfidera™ (dimethyl fumarate)Drug Facts • Pharmacology: • Exact mechanism unknown • Activates antioxidant pathways that protect CNS cells from autoimmune attack • May also directly inhibit pro-inflammatory pathways

  6. Tecfidera™ (dimethyl fumarate)Drug Facts • Pharmacokinetics • A – rapidly converted to monomethyl fumarate during absorption; high fat/calorie meal slows absorption but no change in AUC. • D – moderate protein binding and lipophilicity • M – No CYP involvement; metabolized to endogenous substrates via Krebs cycle • E – primarily via exhaled CO2, some renal

  7. Tecfidera™ (dimethyl fumarate)Drug Interactions • Drug Interactions – Object Drugs • May increase infection from live vaccines • May decrease ability to form humoral immunity from live vaccines • Drug Interactions – Precipitant Drugs • None observed

  8. Tecfidera™ (dimethyl fumarate)Monitoring Parameters • Efficacy Monitoring • Prevention of relapse • Toxicity Monitoring • Baseline CBC (lymphocyte count); recheck annually

  9. Tecfidera™ (dimethyl fumarate)Prescription Information • Twice daily dosing • Initiation: 120 mg BID • Maintenance 240 mg BID • Cost - $5400/month (Medi-Span; accessed 08/01/2013)

  10. Tecfidera™ (dimethyl fumarate)Literature Review: DEFINE • 2-year, multi-center, randomized, double-blind, placebo-controlled trial • [240 mg BID] [240 mg TID] [placebo] • Outcomes • Proportion relapsed at 2 years (primary) • MRI changes • Annualized relapse rate • Time to progression of disability Gold R, et al. N Engl J Med. 2012;367:1098-107.

  11. Tecfidera™ (dimethyl fumarate)Literature Review: DEFINE • N = 1234 • Age 18-55 yr • No progressive disease • Documented relapse within past year • Disability score 0-5 (out of 10), expanded disability status scale Gold R, et al. N Engl J Med. 2012;367:1098-107.

  12. Tecfidera™ (dimethyl fumarate)Literature Review: DEFINE Gold R, et al. N Engl J Med. 2012;367:1098-107.

  13. Tecfidera™ (dimethyl fumarate)Literature Review: DEFINE Primary Outcome: Gold R, et al. N Engl J Med. 2012;367:1098-107.

  14. Tecfidera™ (dimethyl fumarate)Literature Review: DEFINE Secondary Outcomes: Gold R, et al. N Engl J Med. 2012;367:1098-107.

  15. Tecfidera™ (dimethyl fumarate)Summary • New first-line oral agent for relapsing-remitting MS • Dosing: initial 120 mg BID x 7d, then 240 mg BID; no dose adjustments • Flushing is most common side effect; need baseline & annual CBC • Appears to be of similar efficacy to alternative agents, but comparative data is needed

  16. Tecfidera™ (dimethyl fumarate)References • Tecfidera™package insert. Biogen/Idec. March 2013. Accessed at http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=665d7e74-036c-5f68-5b67-ab84b9b49151 • Gold R, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098-107. • Fox R, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367;1087-97.

More Related